سعر ليبيكلير 40/10 مجم 14 قرص 2022

Lipiclear film-coated tablets, amlodipine 10 mg + atorvastatin 40 mg (strength order assumed amlodipine/atorvastatin), pack of 14 (Chemipharm, Egypt); statin combined with a calcium channel blocker.

• Patients for whom treatment with both amlodipine and atorvastatin is appropriate.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Amlodipine component: hypertension (to lower blood pressure and reduce fatal and non-fatal cardiovascular events) and coronary artery disease (chronic stable and vasospastic angina, angiographically documented CAD).Population: AdultsDailyMed (U.S. National Library of Medicine)
• To reduce the risk of MI, stroke, revascularisation procedures and angina in adults with multiple risk factors for coronary heart disease but without clinically evident CHD, and of MI and stroke in adults with type 2 diabetes and multiple risk factors.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Amlodipine component: oedema, dose-related, is the most common adverse reaction.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Most common (5% or more): nasopharyngitis, arthralgia, diarrhoea, pain in extremity and urinary tract infection.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to amlodipine, atorvastatin or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis: risk increases with age 65 or older, uncontrolled hypothyroidism, renal impairment, interacting drugs and higher doses; stop if CK is markedly raised or myopathy is suspected and tell patients to report unexplained muscle pain or weakness.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotising myopathy has been reported rarely with statins; discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: transaminase increases and rare hepatic failure; consider liver tests before starting and as clinically indicated; stop promptly if serious liver injury occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cyclosporine; gemfibrozilRaise the risk of myopathy/rhabdomyolysis; concomitant use is not recommended.DailyMed (U.S. National Library of Medicine)
• Clarithromycin; itraconazoleIncrease atorvastatin exposure; do not exceed 20 mg once daily.DailyMed (U.S. National Library of Medicine)
• HIV/HCV antivirals (e.g. tipranavir/ritonavir, glecaprevir/pibrentasvir; saquinavir/ritonavir, darunavir/ritonavir, fosamprenavir, elbasvir/grazoprevir, letermovir; nelfinavir)Tipranavir/ritonavir and glecaprevir/pibrentasvir not recommended; with saquinavir/ritonavir, darunavir/ritonavir, fosamprenavir, elbasvir/grazoprevir or letermovir do not exceed 20 mg; with nelfinavir do not exceed 40 mg.DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognised (or weigh ongoing need); may cause fetal harm based on mechanism; observational data over decades have not identified a drug-associated risk of major malformations; treatment of hyperlipidaemia is generally unnecessary during pregnancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human data; another statin passes into milk; breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Amlodipine is present in human milk (median relative infant dose about 4.2%) without observed infant adverse effects; overall the combination label advises against breastfeeding because of atorvastatin.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Amlodipine: Inhibits transmembrane calcium influx into vascular smooth muscle and cardiac muscle; peripheral arterial vasodilator.
• Atorvastatin: Inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and increasing hepatic LDL-receptor uptake of LDL.